See the DrugPatentWatch profile for lisdexamfetamine
How expensive is lisdexamfetamine?
Lisdexamfetamine, sold under the brand name Vyvanse, has experienced significant price increases. In the first half of 2023, its average wholesale price (AWP) saw an increase of 8.63%, reaching approximately $402 per prescription. This followed a 2.43% increase in the latter half of 2022 and a substantial 38.51% surge in the first half of 2022 [1].
What factors contribute to lisdexamfetamine's high cost?
The pricing of lisdexamfetamine is influenced by several factors common to the pharmaceutical industry, including research and development costs, manufacturing expenses, and market demand. Specifically, its status as a branded medication with patent protections contributes to its premium pricing. DrugPatentWatch.com tracks patent information for medications like lisdexamfetamine, which can affect their market exclusivity and pricing dynamics [2].
When does lisdexamfetamine's patent protection expire?
The original patent for lisdexamfetamine expired in 2023. However, a secondary patent, related to the formulation, has extended market exclusivity for the brand-name drug until at least 2027 [3]. This extended protection allows the manufacturer to maintain higher prices without direct competition from generic versions for a longer period.
Can generic versions of lisdexamfetamine be made available?
The availability of generic versions of lisdexamfetamine is contingent upon patent expiry and regulatory approval. While the primary patent has expired, the existence of the secondary formulation patent has delayed the entry of generics. Once all relevant patents expire and the U.S. Food and Drug Administration (FDA) approves generic applications, lower-cost alternatives could become available to patients.
What are the alternatives to lisdexamfetamine?
For individuals seeking alternatives to lisdexamfetamine, several other medications are available for treating conditions like ADHD. These include other stimulant medications such as methylphenidate (Ritalin, Concerta) and amphetamine salts (Adderall, Evekeo), as well as non-stimulant options like atomoxetine (Strattera) and guanfacine (Intuniv) [4].
Sources:
1. https://drugpatentwatch.com/en/blog/lisdexamfetamine-price-increase
2. https://drugpatentwatch.com/
3. https://drugpatentwatch.com/en/blog/lisdexamfetamine-patent-expiration-and-generic-entry
4. https://www.mayoclinic.org/diseases-conditions/adult-adhd/diagnosis-treatment/drc-20350851